erlotinib hydrochloride has been researched along with Proteinuria in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H; Domoto, Y; Hirakawa, Y; Honda, K; Miyashita, N; Nagase, T; Nakamura, M; Nangaku, M; Oda, Y; Oki, R | 1 |
| Bou Matar, RN; Klein, JD; Sands, JM | 1 |
2 other study(ies) available for erlotinib hydrochloride and Proteinuria
| Article | Year |
|---|---|
Renal-limited ANCA-associated vasculitis during erlotinib treatment for lung carcinoma.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Glomerulonephritis; Hematuria; Humans; Kidney; Lung; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteinuria | 2022 |
Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats.
Topics: Animals; Antibiotics, Antineoplastic; Aquaporin 2; Creatinine; Doxorubicin; Epithelial Sodium Channels; ErbB Receptors; Erlotinib Hydrochloride; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Male; Nephrotic Syndrome; Protein Kinase Inhibitors; Proteinuria; Quinazolines; Rats; Renal Insufficiency; Sodium Chloride Symporters; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 1 | 2013 |